Vivimed Labs (NSE:VIVIMEDLAB) Ending Cash Position: ₹0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:VIVIMEDLAB Vivimed Labs Ltd NSE:VIVIMEDLAB
39 GF Score
Price ₹5.13
GF Value ₹2.44
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Vivimed Labs Ending Cash Position?

Vivimed Labs NSE:VIVIMEDLAB -2.47% 39 Ending Cash Position is ₹0.0 Mil as of Mar. 2026. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 39/100 and a GF Value™ of ₹2.44 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Vivimed Labs's Ending Cash Position for the quarter that ended in Mar. 2026 was ₹0.0 Mil.

Vivimed Labs's annual Ending Cash Position declined from Mar. 2024 (₹20.3 Mil) to Mar. 2025 (₹7.1 Mil) but then increased from Mar. 2025 (₹7.1 Mil) to Mar. 2026 (₹13.6 Mil).

Vivimed Labs Ending Cash Position Related Terms

Vivimed Labs Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Vivimed Labs's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivimed Labs Ending Cash Position Chart

Vivimed Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.84 37.62 20.26 7.08 13.56

Vivimed Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:VIVIMEDLAB
39GF Score
Vivimed Labs Ltd NSE:VIVIMEDLAB
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivimed Labs Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Vivimed Labs's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=7.07+6.49
=13.6

Vivimed Labs's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0.0

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ₹0.0 Mil mean?
Vivimed Labs (NSE:VIVIMEDLAB) has a Ending Cash Position of ₹0.0 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vivimed Labs and its competitors.
Is Vivimed Labs' Ending Cash Position too high?
Vivimed Labs' current Ending Cash Position is ₹0.0 Mil. Overall, Vivimed Labs has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' Ending Cash Position compare to ZTS and UTHR?
Vivimed Labs' Ending Cash Position of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vivimed Labs and its competitors. Vivimed Labs's current Ending Cash Position is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.44, compared to a current price of ₹5.13 — trading 110.2% above its estimated fair value. The current Ending Cash Position is ₹0.0 Mil. Vivimed Labs' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current Ending Cash Position is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued. The current stock price of ₹5.13 is trading 110.2% above its estimated GF Value™ of ₹2.44. GuruFocus considers Vivimed Labs to be Significantly Overvalued.

Key valuation signals for NSE:VIVIMEDLAB:

  • Ending Cash Position: ₹0.0 Mil
  • GF Value™: ₹2.44 vs. price of ₹5.13 (110.2% above fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivimed Labs Business Description

Other Exchanges 532660:India
Address Green Lands, Beside The Plaza Hotel, D.No. 6-3-866/1/G1, 3rd & 4th Floor, GMR Towers, Begumpet, Hyderabad, TG, IND, 500016
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
39GF Score

Get the complete analysis for NSE:VIVIMEDLAB

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5.13
Price
₹2.44
GF Value